(2S,4R)-N-((S)-3-(4-((4-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutylcarbamoyl)phenyl)ethynyl)-1,4'-bipiperidin-1'-yl)-1-(4-(4-methylthiazol-5-yl)phenyl)-3-oxopropyl)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide

ID: ALA4751950

PubChem CID: 162652844

Max Phase: Preclinical

Molecular Formula: C63H74ClN9O7S

Molecular Weight: 1136.86

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1ncsc1-c1ccc([C@H](CC(=O)N2CCC(N3CCC(C#Cc4ccc(C(=O)N[C@H]5C(C)(C)[C@H](Oc6ccc(C#N)c(Cl)c6)C5(C)C)cc4)CC3)CC2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(C#N)CC2)C(C)(C)C)cc1

Standard InChI:  InChI=1S/C63H74ClN9O7S/c1-38-52(81-37-67-38)42-17-15-41(16-18-42)49(68-55(77)50-31-46(74)35-73(50)56(78)53(60(2,3)4)69-59(79)63(36-66)25-26-63)33-51(75)72-29-23-45(24-30-72)71-27-21-40(22-28-71)10-9-39-11-13-43(14-12-39)54(76)70-57-61(5,6)58(62(57,7)8)80-47-20-19-44(34-65)48(64)32-47/h11-20,32,37,40,45-46,49-50,53,57-58,74H,21-31,33,35H2,1-8H3,(H,68,77)(H,69,79)(H,70,76)/t46-,49+,50+,53-,57-,58-/m1/s1

Standard InChI Key:  YLIIPOUNLYQGIU-NMPLUEPVSA-N

Molfile:  

 
     RDKit          2D

 81 89  0  0  0  0  0  0  0  0999 V2000
   39.5111   -9.7728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.0476  -10.4506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.8663  -10.5131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.2205  -13.1057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.4146  -13.2563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.9480  -13.8790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6763  -11.1775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.0298  -11.9189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.8482  -11.9813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.1413  -10.4986    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.2017  -12.7227    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.7327  -13.3999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.0856  -14.1407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9048  -14.2037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.3717  -13.5235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.0163  -12.7854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.3149  -11.3062    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.1333  -11.3686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.5962  -10.6952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.4162  -10.6687    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.6503   -9.8797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9749   -9.4222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.3211   -9.9177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.9204  -11.3180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.6073  -12.0791    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   38.7304  -11.2097    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.5448   -9.8012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.2611  -14.9425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.8701  -15.6666    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   36.4351  -16.2625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.1761  -15.9080    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.0703  -15.0925    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.6679  -14.5312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.4867  -12.1100    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   36.9532   -8.6053    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   39.2281  -11.8578    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   38.9156  -12.6129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.1054  -12.7198    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   39.1008  -14.0162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.7913  -14.7752    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.8985  -11.8994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.3031  -11.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8925  -10.4812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0734  -10.4857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.6666  -11.2022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0836  -11.9056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.1201  -11.1819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9414  -11.1779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.7627  -11.1739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.1741  -11.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9919  -11.8854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.4008  -11.1734    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.9900  -10.4618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.1660  -10.4622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2175  -11.1716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6298  -11.8848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4475  -11.8858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.8591  -11.1753    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.4510  -10.4622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6270  -10.4595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6184   -9.1996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.0353   -9.9136    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4437   -9.1971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4397  -11.7832    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.0353  -11.0734    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6222  -11.7806    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4556  -10.4955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6153  -10.4955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4366  -10.4955    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.6343  -10.4955    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.2215  -11.2033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4011  -11.1983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.9926  -11.9093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4012  -12.6221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2268  -12.6194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6357  -11.9079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.1713  -11.9089    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   18.9936  -13.3345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5852  -14.0487    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.8494  -11.2033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4366  -11.9151    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  5  4  1  0
  6  5  1  0
  4  6  1  0
  7  8  1  0
  9  8  1  6
  7 10  2  0
  9 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 11  1  0
  9 17  1  0
 17 18  1  0
 19 18  1  6
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 19  1  0
 20 24  1  0
 24 25  2  0
 24 26  1  0
 26  2  1  0
  2 27  1  0
 28 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 28  2  0
 14 28  1  0
 32 33  1  0
 18 34  2  0
 22 35  1  1
 26 36  1  6
 36 37  1  0
 37 38  2  0
 37  5  1  0
  5 39  1  0
 39 40  3  0
 41 42  2  0
 42 43  1  0
 43 44  2  0
 44 45  1  0
 45 46  2  0
 46 41  1  0
 47 48  3  0
 42 47  1  0
 48 49  1  0
 49 50  1  0
 49 54  1  0
 50 51  1  0
 51 52  1  0
 52 53  1  0
 53 54  1  0
 55 56  1  0
 55 60  1  0
 56 57  1  0
 57 58  1  0
 58 59  1  0
 59 60  1  0
 52 55  1  0
 62 61  1  0
 63 62  1  0
 65 64  1  0
 66 65  1  0
 67 65  1  0
 65 68  1  0
 68 62  1  0
 62 67  1  0
 68 69  1  1
 67 70  1  6
 70 71  1  0
 71 72  2  0
 72 73  1  0
 73 74  2  0
 74 75  1  0
 75 76  2  0
 76 71  1  0
 73 77  1  0
 74 78  1  0
 78 79  3  0
 69 80  1  0
 80 81  2  0
 80 45  1  0
 58  7  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4751950

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1136.86

Molecular Weight (Monoisotopic): 1135.5120

AlogP: ┄

#Rotatable Bonds: ┄

Polar Surface Area: ┄

Molecular Species: ┄

HBA: ┄

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): ┄

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: ┄

CX LogD: ┄

Aromatic Rings: ┄

Heavy Atoms: ┄

QED Weighted: ┄

Np Likeness Score: ┄

References

1. Kargbo RB.  (2021)  Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.,  12  (3): [PMID:33738051] [10.1021/acsmedchemlett.1c00059]

2. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S..  (2019)  Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.,  62  (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631]

3. Tilley, W D WD, Marcelli, M M, Wilson, J D JD and McPhaul, M J MJ.  1989-01  Characterization and expression of a cDNA encoding the human androgen receptor.  [PMID:2911578]

4. Hamann, L G LG and 8 more authors.  1998-02-12  Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.  [PMID:9484511]

5. Wang, L G LG, Liu, X M XM, Kreis, W W and Budman, D R DR.  1998-05-01  Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.  [PMID:10076535]

6. Giwercman, A A and 7 more authors.  2000-06  Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene.  [PMID:10852459]

7. Fuhrmann, U U and 7 more authors.  2000-12-28  Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.  [PMID:11150172]

8. Handratta, Venkatesh D VD and 10 more authors.  2005-04-21  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.  [PMID:15828836]

9. Kinoyama, Isao I and 16 more authors.  2006-01-26  (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.  [PMID:16420057]

10. Larsson, Anders A, Eriksson, Leif A LA, Andersson, Patrik L PL, Ivarson, Per P and Olsson, Per-Erik PE.  2006-12-14  Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.  [PMID:17149866]

11. van Oeveren, Arjan A and 11 more authors.  2007-03-15  Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.  [PMID:17267219]

12. Fensome, Andrew A and 19 more authors.  2008-03-27  Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).  [PMID:18318463]

13. Li, Jie Jack JJ and 23 more authors.  2008-11-13  Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications.  [PMID:18921992]

14. Tran, Chris C and 18 more authors.  2009-05-08  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.  [PMID:19359544]

15. Schlienger, Nathalie N and 12 more authors.  2009-11-26  Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.  [PMID:19856921]

16. Jung, Michael E and 6 more authors.  2010-04-08  Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).  [PMID:20218717]

17. Zhou, Hai-Bing HB, Lee, Jae Hak JH, Mayne, Christopher G CG, Carlson, Kathryn E KE and Katzenellenbogen, John A JA.  2010-04-22  Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.  [PMID:20355713]

18. Arhancet, Graciela B and 14 more authors.  2010-08-26  Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.  [PMID:20672820]

19. Yoshino, Hitoshi H and 16 more authors.  2010-12-01  Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.  [PMID:21050768]

20. Guo, Chuangxing C and 28 more authors.  2011-11-10  Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.  [PMID:21936524]

21. Hasui, Tomoaki and 18 more authors.  2011-12-22  Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.  [PMID:22074142]

22. Yamamoto, Satoshi S and 13 more authors.  2012-01-01  Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.  [PMID:22094279]

23. Guo, Chuangxing C and 11 more authors.  2012-01-15  Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.  [PMID:22197140]

24. Yamamoto, Satoshi S and 10 more authors.  2012-04-01  Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.  [PMID:22391033]

25. Poutiainen, Pekka K PK and 6 more authors.  2012-07-26  Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators.  [PMID:22746350]

26. Yamamoto, Satoshi S and 9 more authors.  2013-01-01  Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.  [PMID:23199477]

27. Liedtke, Andy J AJ and 7 more authors.  2013-03-28  Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.  [PMID:23432095]

28. Purushottamachar, Puranik P and 8 more authors.  2013-06-27  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.  [PMID:23713567]

29. Maruyama, Keisuke K and 6 more authors.  2013-07-15  Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERα-selective antagonist.  [PMID:23768907]

30. Akita, Kazumasa K and 5 more authors.  2013-11-15  A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate.  [PMID:24177288]

31. Richardson, Timothy I TI and 18 more authors.  2011-02-10  Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.  [PMID:24900294]

32. Li, Huifang H and 8 more authors.  2014-08-14  Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.  [PMID:25062331]

33. Ullrich, Thomas T and 21 more authors.  2014-09-11  3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.  [PMID:25121964]

34. Gege, Christian C, Schlüter, Thomas T and Hoffmann, Thomas T.  2014-11-15  Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.  [PMID:25305688]

35. Sundén, Henrik H and 6 more authors.  2015-02-12  Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.  [PMID:25646649]

36. Aikawa, Katsuji K and 11 more authors.  2015-05-15  Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I.  [PMID:25862209]

37. Jadhavar, Pradeep S PS and 20 more authors.  2016-11-01  Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.  [PMID:27717544]

38. Shibata, Norihito N and 11 more authors.  2018-01-25  Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.  [PMID:28594553]

39. Unwalla, Ray R and 18 more authors.  2017-07-27  Structure-Based Approach To Identify 5-[4-Hydroxyphenyl]pyrrole-2-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators.  [PMID:28696695]

40. Nishiyama, Yuko Y and 6 more authors.  2018-07-12  Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.  [PMID:30034593]

41. Rew, Yosup Y and 19 more authors.  2018-09-13  Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).  [PMID:30091920]

42. Dalal, Kush K and 11 more authors.  2018-09-05  Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.  [PMID:30193215]

43. Hwang, Dong-Jin DJ and 7 more authors.  2019-01-24  New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.  [PMID:30525603]

44. Yu, Jiang J and 7 more authors.  2019-06-01  Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.  [PMID:30925341]

45. Du, Xiaohui X and 16 more authors.  2019-07-25  Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).  [PMID:31274313]

46. Tang, Qin and 12 more authors.  2020-04-15  Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.  [PMID:32114360]

47. He, Yali and 6 more authors.  2020-11-12  Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.  [PMID:33095584]

48. Wang, Ao; Wang, Yawan; Meng, Xin and Yang, Yushe.  2021-02-01  Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.  [PMID:33388655]

49. Zhang, Zhuming and 17 more authors.  2021-01-28  Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).  [PMID:33470111]

Source

Source(1):

• Scientific Literature